Loxapine (Adasuve) vs Lurasidone

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Loxapine (Adasuve)

Marketed by Lee's Pharmaceutical and partners

Phase 3 in Schizophreniasmall molecule
Reliable signal

NCT00628589 · Phase 3 · completed

The trial randomly assigned 344 participants to inhaled loxapine 5 mg, loxapine 10 mg, or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary clinical agitation measure was significantly improved with both loxapine doses compared with placebo (p=0.0004 and p<0.0001).

Reported efficacy

Change in PANSS-EC From Baseline (Baseline and 2 hours): Change in PANSS-EC From Baseline (Baseline and 2 hours): Inhaled Loxapine 5 mg -8.1 units on a scale (Standard Deviation 5.17) | Inhaled Loxapine 10 mg -8.6 units on a scale (Standard Deviation 4.37) vs Inhaled Placebo -5.5 units on a scale (Standard Deviation 4.92) (met)

Result source: NCT00628589

Lurasidone

Marketed by Sumitomo Pharma and partners

Approved in Schizophreniasmall molecule
Reliable signal

NCT00549718 · Phase 3 · completed

The study randomized approximately 500 participants to lurasidone 40, 80, or 120 mg or placebo and used quadruple masking of participants, clinicians, investigators, and outcome assessors. Its clinical primary endpoint, change in total PANSS score over 6 weeks, favored lurasidone overall versus placebo and was statistically significant (p<0.05).

Reported efficacy

Mean change in Total PANSS Score From Baseline at Week 6: Change in PANSS total score at week 6 (prespecified primary analysis in the per-protocol set): -26.42±2.02 lurasidone vs -27.33±2.01 quetiapine XR (adjusted mean±SE); difference -0.91 (95% CI -6.35 to 4.53); lower limit above the -8.99 non-inferiority margin, met. The ITT set analysis also showed non-inferiority. (met)

Result source: NCT03465787

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLoxapine (Adasuve)Lurasidone
PANSS total, change—Not reported-26.5 vs -10.3−16.2 vs placebo160 mg · wk 6 · n 121NCT00790192
24 other results
  • -19.2 vs -17 40mg · wk 6 · n 121 · Phase 3 · primary NCT00549718
  • -25.7 vs -16 40 mg · wk 6 · n 118 · Phase 3 · primary NCT00615433
  • -18.6 vs -10.5 40 mg · wk 6 · n 108 · Phase 3 · primary NCT01911429
  • -17.9 vs -13.1 40 mg · wk 6 · n 145 · Phase 3 · primary NCT01614899
  • -6.1 vs -2.5 40 mg · wk 6 · n 125 · Phase 3 · primary NCT00711269
  • -20.5 vs -17 120mg · wk 6 · n 123 · Phase 3 · primary NCT00549718
  • -23.6 vs -16 120 mg · wk 6 · n 118 · Phase 3 · primary NCT00615433
  • -23.4 vs -17 80mg · wk 6 · n 118 · Phase 3 · primary NCT00549718
  • -18.3 vs -10.5 80 mg · wk 6 · n 106 · Phase 3 · primary NCT01911429
  • -17.3 vs -13.1 80 mg · wk 6 · n 152 · Phase 3 · primary NCT01614899
  • -22.2 vs -10.3 80 mg · wk 6 · n 125 · Phase 3 · primary NCT00790192
  • -4.3 vs -2.5 80 mg · wk 6 · n 129 · Phase 3 · primary NCT00711269
  • -17.6 vs -14.5 20 mg · wk 6 · n 101 · Phase 3 · primary NCT01821378
  • -24.9 vs -14.5 80-160 mg · wk 6 · n 198 · Phase 3 · primary NCT01821378
  • -31.2 vs -34.9 wk 6 · n 194 · Phase 3 · primary NCT02002832
  • -21.7 vs -14.4 160 mg · wk 6 · n 43 · Phase 3 · secondary NCT01821378
  • -14.4 vs -14.4 80 mg · wk 6 · n 52 · Phase 3 · secondary NCT01821378
  • 8.3 vs 12.4 wk 28 · n 144 · Phase 3 · secondary NCT01435928
  • -34.6 vs -25.7 wk 52 · n 132 · Phase 3 · secondary NCT00789698
  • -14.1 vs -5.5 80 mg · wk 6 · n 90 · Phase 2 · secondary NCT00088634
  • -7.1 vs -12.3 wk 6 · n 71 · Phase 2 · secondary NCT00044044
  • -7.2 vs -12.3 wk 6 · n 65 · Phase 2 · secondary NCT00044044
  • -13.6 vs -12.3 wk 6 · n 70 · Phase 2 · secondary NCT00044044
  • -26.4 vs -27.3 wk 6 · Phase 3 · primary NCT03465787
CGI-S, change—Not reported-1.1 vs -1−0.1 vs placebo40mg · wk 6 · n 122NCT00549718
20 other results
  • -1.5 vs -1.1 40 mg · wk 6 · n 119 · Phase 3 · secondary NCT00615433
  • -1.0 vs -0.5 40 mg · wk 6 · n 108 · Phase 3 · secondary NCT01911429
  • -0.9 vs -0.8 40 mg · wk 6 · n 140 · Phase 3 · secondary NCT01614899
  • -1.3 vs -0.7 160 mg · wk 6 · n 43 · Phase 3 · secondary NCT01821378
  • -1.7 vs -0.9 160 mg · wk 6 · n 121 · Phase 3 · secondary NCT00790192
  • -1.2 vs -1 120mg · wk 6 · n 124 · Phase 3 · secondary NCT00549718
  • -1.4 vs -1.1 120 mg · wk 6 · n 118 · Phase 3 · secondary NCT00615433
  • -1.4 vs -1 80mg · wk 6 · n 119 · Phase 3 · secondary NCT00549718
  • -0.9 vs -0.5 80 mg · wk 6 · n 106 · Phase 3 · secondary NCT01911429
  • -1.0 vs -0.8 80 mg · wk 6 · n 150 · Phase 3 · secondary NCT01614899
  • -1.5 vs -0.9 80 mg · wk 6 · n 125 · Phase 3 · secondary NCT00790192
  • -0.9 vs -0.7 20 mg · wk 6 · n 101 · Phase 3 · secondary NCT01821378
  • -1.3 vs -0.7 80-160 mg · wk 6 · n 198 · Phase 3 · secondary NCT01821378
  • -0.8 vs -0.7 80 mg · wk 6 · n 52 · Phase 3 · secondary NCT01821378
  • 0.4 vs 0.7 wk 28 · n 144 · Phase 3 · secondary NCT01435928
  • -1.9 vs -1.6 wk 52 · n 132 · Phase 3 · secondary NCT00789698
  • -0.6 vs -0.2 80 mg · wk 6 · n 90 · Phase 2 · secondary NCT00088634
  • -0.5 vs -0.7 wk 6 · n 71 · Phase 2 · secondary NCT00044044
  • -0.4 vs -0.7 wk 6 · n 64 · Phase 2 · secondary NCT00044044
  • -0.8 vs -0.7 wk 6 · n 70 · Phase 2 · secondary NCT00044044
PANSS response—Not reported—Not posted · NCT01143090
PSP, change—Not reported—Not posted · NCT01143090
Relapse (% of patients)—Not reported20.9% vs 26.6%vs Quetiapinewk 52 · n 139NCT00789698

PANSS total, change

Loxapine (Adasuve)
—Not reported
Lurasidone
-26.5 vs -10.3−16.2 vs placebo160 mg · wk 6 · n 121NCT00790192
24 other results
  • -19.2 vs -17 40mg · wk 6 · n 121 · Phase 3 · primary NCT00549718
  • -25.7 vs -16 40 mg · wk 6 · n 118 · Phase 3 · primary NCT00615433
  • -18.6 vs -10.5 40 mg · wk 6 · n 108 · Phase 3 · primary NCT01911429
  • -17.9 vs -13.1 40 mg · wk 6 · n 145 · Phase 3 · primary NCT01614899
  • -6.1 vs -2.5 40 mg · wk 6 · n 125 · Phase 3 · primary NCT00711269
  • -20.5 vs -17 120mg · wk 6 · n 123 · Phase 3 · primary NCT00549718
  • -23.6 vs -16 120 mg · wk 6 · n 118 · Phase 3 · primary NCT00615433
  • -23.4 vs -17 80mg · wk 6 · n 118 · Phase 3 · primary NCT00549718
  • -18.3 vs -10.5 80 mg · wk 6 · n 106 · Phase 3 · primary NCT01911429
  • -17.3 vs -13.1 80 mg · wk 6 · n 152 · Phase 3 · primary NCT01614899
  • -22.2 vs -10.3 80 mg · wk 6 · n 125 · Phase 3 · primary NCT00790192
  • -4.3 vs -2.5 80 mg · wk 6 · n 129 · Phase 3 · primary NCT00711269
  • -17.6 vs -14.5 20 mg · wk 6 · n 101 · Phase 3 · primary NCT01821378
  • -24.9 vs -14.5 80-160 mg · wk 6 · n 198 · Phase 3 · primary NCT01821378
  • -31.2 vs -34.9 wk 6 · n 194 · Phase 3 · primary NCT02002832
  • -21.7 vs -14.4 160 mg · wk 6 · n 43 · Phase 3 · secondary NCT01821378
  • -14.4 vs -14.4 80 mg · wk 6 · n 52 · Phase 3 · secondary NCT01821378
  • 8.3 vs 12.4 wk 28 · n 144 · Phase 3 · secondary NCT01435928
  • -34.6 vs -25.7 wk 52 · n 132 · Phase 3 · secondary NCT00789698
  • -14.1 vs -5.5 80 mg · wk 6 · n 90 · Phase 2 · secondary NCT00088634
  • -7.1 vs -12.3 wk 6 · n 71 · Phase 2 · secondary NCT00044044
  • -7.2 vs -12.3 wk 6 · n 65 · Phase 2 · secondary NCT00044044
  • -13.6 vs -12.3 wk 6 · n 70 · Phase 2 · secondary NCT00044044
  • -26.4 vs -27.3 wk 6 · Phase 3 · primary NCT03465787

CGI-S, change

Loxapine (Adasuve)
—Not reported
Lurasidone
-1.1 vs -1−0.1 vs placebo40mg · wk 6 · n 122NCT00549718
20 other results
  • -1.5 vs -1.1 40 mg · wk 6 · n 119 · Phase 3 · secondary NCT00615433
  • -1.0 vs -0.5 40 mg · wk 6 · n 108 · Phase 3 · secondary NCT01911429
  • -0.9 vs -0.8 40 mg · wk 6 · n 140 · Phase 3 · secondary NCT01614899
  • -1.3 vs -0.7 160 mg · wk 6 · n 43 · Phase 3 · secondary NCT01821378
  • -1.7 vs -0.9 160 mg · wk 6 · n 121 · Phase 3 · secondary NCT00790192
  • -1.2 vs -1 120mg · wk 6 · n 124 · Phase 3 · secondary NCT00549718
  • -1.4 vs -1.1 120 mg · wk 6 · n 118 · Phase 3 · secondary NCT00615433
  • -1.4 vs -1 80mg · wk 6 · n 119 · Phase 3 · secondary NCT00549718
  • -0.9 vs -0.5 80 mg · wk 6 · n 106 · Phase 3 · secondary NCT01911429
  • -1.0 vs -0.8 80 mg · wk 6 · n 150 · Phase 3 · secondary NCT01614899
  • -1.5 vs -0.9 80 mg · wk 6 · n 125 · Phase 3 · secondary NCT00790192
  • -0.9 vs -0.7 20 mg · wk 6 · n 101 · Phase 3 · secondary NCT01821378
  • -1.3 vs -0.7 80-160 mg · wk 6 · n 198 · Phase 3 · secondary NCT01821378
  • -0.8 vs -0.7 80 mg · wk 6 · n 52 · Phase 3 · secondary NCT01821378
  • 0.4 vs 0.7 wk 28 · n 144 · Phase 3 · secondary NCT01435928
  • -1.9 vs -1.6 wk 52 · n 132 · Phase 3 · secondary NCT00789698
  • -0.6 vs -0.2 80 mg · wk 6 · n 90 · Phase 2 · secondary NCT00088634
  • -0.5 vs -0.7 wk 6 · n 71 · Phase 2 · secondary NCT00044044
  • -0.4 vs -0.7 wk 6 · n 64 · Phase 2 · secondary NCT00044044
  • -0.8 vs -0.7 wk 6 · n 70 · Phase 2 · secondary NCT00044044

PANSS response

Loxapine (Adasuve)
—Not reported
Lurasidone
—Not posted · NCT01143090

PSP, change

Loxapine (Adasuve)
—Not reported
Lurasidone
—Not posted · NCT01143090

Relapse (% of patients)

Loxapine (Adasuve)
—Not reported
Lurasidone
20.9% vs 26.6%vs Quetiapinewk 52 · n 139NCT00789698
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Loxapine (Adasuve): 4 of 5 rows · Lurasidone: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLoxapine (Adasuve)Lurasidone
CGI-I
absolute value · score
2.1 vs 2.8 placebo score @ 0.0119wk10 mga,b,c,d
NCT00628589 · Phase 3 · monotherapy
show 1 more dose
2.3 vs 2.8 placebo score @ 0.0119wk5 mg
NCT00628589 · Phase 3 · monotherapy
2 vs 1.9 Risperidone score @ 6wkb,c,d
NCT02002832 · Phase 3 · registry result, not featured evidence
Dropout rate
2.7%10 mge
NCT00628589 · Phase 3 · monotherapy
show 8 more results
1.7%5 mg
NCT00628589 · Phase 3 · monotherapy
2.4%10 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%5 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%2.5 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%1.25 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%0.625 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
32.8%40mge
NCT00549718 · Phase 3 · monotherapy
show 42 more results
31.5%120mg
NCT00549718 · Phase 3 · monotherapy
30.1%80mg
NCT00549718 · Phase 3 · monotherapy
35.8%40 mg
NCT00615433 · Phase 3 · monotherapy
44.5%120 mg
NCT00615433 · Phase 3 · monotherapy
0%Lurasidone
NCT02199743 · Phase 4 · registry result, not featured evidence
—Lurasidone (LUR)
NCT02199743 · Phase 4 · registry result, not featured evidence
33.3%
NCT01569659 · Phase 4 · registry result, not featured evidence
11.1%40 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
9.4%80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
14.4%
NCT02002832 · Phase 3 · registry result, not featured evidence
44%40-mg or 80-mg
NCT01614912 · Phase 3 · registry result, not featured evidence
29.3%40 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
25.2%80 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
26.7%20 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
—80-160 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
75.3%
NCT01485640 · Phase 3 · registry result, not featured evidence
18.8%
NCT01566162 · Phase 3 · registry result, not featured evidence
—
NCT01435928 · Phase 3 · registry result, not featured evidence
41.8%160 mg
NCT00789698 · Phase 3 · registry result, not featured evidence
55.6%80 mg
NCT00789698 · Phase 3 · registry result, not featured evidence
21.6%40/40
NCT01143077 · Phase 3 · registry result, not featured evidence
17%40/80
NCT01143077 · Phase 3 · registry result, not featured evidence
18.3%80/80
NCT01143077 · Phase 3 · registry result, not featured evidence
65.6%
NCT00641745 · Phase 3 · registry result, not featured evidence
23.1%160 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
28.8%80 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
33.6%40 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
36.6%80 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
22.2%flexible dose
NCT01731119 · Phase 2 · registry result, not featured evidence
88.5%80 mg
NCT00088621 · Phase 2 · registry result, not featured evidence
42.2%80 mg
NCT00088634 · Phase 2 · registry result, not featured evidence
42.4%40 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
66.7%80 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
59.4%20 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
62%20 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
59.4%40 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
56.3%80 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
0%40 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
0%80 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
0%20 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
10%40mg
NCT02174523 · Phase 1 · registry result, not featured evidence
14.3%
NCT01620060 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—10 mge
NCT00628589 · Phase 3 · monotherapy
show 8 more results
—5 mg
NCT00628589 · Phase 3 · monotherapy
—10 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
—5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
—10 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
—5 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
—2.5 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
—1.25 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
—0.625 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
4.8%40mge
NCT00549718 · Phase 3 · monotherapy
show 42 more results
5.6%120mg
NCT00549718 · Phase 3 · monotherapy
6.5%80mg
NCT00549718 · Phase 3 · monotherapy
—40 mg
NCT00615433 · Phase 3 · monotherapy
—120 mg
NCT00615433 · Phase 3 · monotherapy
—Lurasidone
NCT02199743 · Phase 4 · registry result, not featured evidence
—Lurasidone (LUR)
NCT02199743 · Phase 4 · registry result, not featured evidence
—
NCT01569659 · Phase 4 · registry result, not featured evidence
4.6%40 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
2.8%80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
—
NCT02002832 · Phase 3 · registry result, not featured evidence
—40-mg or 80-mg
NCT01614912 · Phase 3 · registry result, not featured evidence
—40 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
—20 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
—80-160 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
6.2%
NCT01485640 · Phase 3 · registry result, not featured evidence
—
NCT01566162 · Phase 3 · registry result, not featured evidence
—
NCT01435928 · Phase 3 · registry result, not featured evidence
6.3%160 mg
NCT00789698 · Phase 3 · registry result, not featured evidence
6.9%80 mg
NCT00789698 · Phase 3 · registry result, not featured evidence
6.8%40/40
NCT01143077 · Phase 3 · registry result, not featured evidence
6.8%40/80
NCT01143077 · Phase 3 · registry result, not featured evidence
6.1%80/80
NCT01143077 · Phase 3 · registry result, not featured evidence
—
NCT00641745 · Phase 3 · registry result, not featured evidence
—160 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
—80 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
—40 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
—80 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
—flexible dose
NCT01731119 · Phase 2 · registry result, not featured evidence
—80 mg
NCT00088621 · Phase 2 · registry result, not featured evidence
—80 mg
NCT00088634 · Phase 2 · registry result, not featured evidence
—40 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
—80 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
—20 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
—20 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
—40 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
—80 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
—40 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
—80 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
—20 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
—40mg
NCT02174523 · Phase 1 · registry result, not featured evidence
8.6%
NCT01620060 · Phase 1 · registry result, not featured evidence
Serious AEs
0.9%10 mge
NCT00628589 · Phase 3 · monotherapy
show 8 more results
0%5 mg
NCT00628589 · Phase 3 · monotherapy
2.4%10 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
2.2%5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%5 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%2.5 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%1.25 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%0.625 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
1.6%40mge
NCT00549718 · Phase 3 · monotherapy
show 42 more results
4.8%120mg
NCT00549718 · Phase 3 · monotherapy
2.5%80mg
NCT00549718 · Phase 3 · monotherapy
1.7%40 mg
NCT00615433 · Phase 3 · monotherapy
5.1%120 mg
NCT00615433 · Phase 3 · monotherapy
—Lurasidone
NCT02199743 · Phase 4 · registry result, not featured evidence
7.1%Lurasidone (LUR)
NCT02199743 · Phase 4 · registry result, not featured evidence
3%
NCT01569659 · Phase 4 · registry result, not featured evidence
3.6%40 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
1.9%80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
0.5%
NCT02002832 · Phase 3 · registry result, not featured evidence
11%40-mg or 80-mg
NCT01614912 · Phase 3 · registry result, not featured evidence
2.7%40 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
1.9%80 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
3%20 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
3%80-160 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
4.3%
NCT01485640 · Phase 3 · registry result, not featured evidence
6.8%
NCT01566162 · Phase 3 · registry result, not featured evidence
4.2%
NCT01435928 · Phase 3 · registry result, not featured evidence
7.6%160 mg
NCT00789698 · Phase 3 · registry result, not featured evidence
12.5%80 mg
NCT00789698 · Phase 3 · registry result, not featured evidence
4.2%40/40
NCT01143077 · Phase 3 · registry result, not featured evidence
2.3%40/80
NCT01143077 · Phase 3 · registry result, not featured evidence
0%80/80
NCT01143077 · Phase 3 · registry result, not featured evidence
11%
NCT00641745 · Phase 3 · registry result, not featured evidence
3.3%160 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
0.8%80 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
6.3%40 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
5.3%80 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
0%flexible dose
NCT01731119 · Phase 2 · registry result, not featured evidence
20.3%80 mg
NCT00088621 · Phase 2 · registry result, not featured evidence
2.2%80 mg
NCT00088634 · Phase 2 · registry result, not featured evidence
18.2%40 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
9.1%80 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
9.4%20 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
5.6%20 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
13.4%40 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
4.2%80 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
0%40 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
0%80 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
0%20 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
0%40mg
NCT02174523 · Phase 1 · registry result, not featured evidence
1.9%
NCT01620060 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
10 mge
dizziness 10.6% (placebo 9.6%)
dysgeusia 10.6% (placebo 2.6%)
sedation 10.6% (placebo 9.6%)
NCT00628589 · Phase 3 · monotherapy
show 8 more results
5 mg
sedation 12.9% (placebo 9.6%)
dysgeusia 8.6% (placebo 2.6%)
dizziness 5.2% (placebo 9.6%)
NCT00628589 · Phase 3 · monotherapy
10 mg
sedation 22% (placebo 14%)
dysgeusia 17.1% (placebo 9.3%)
headache 12.2% (placebo 2.3%)
NCT00369577 · Phase 2 · registry result, not featured evidence
5 mg
sedation 13.3% (placebo 14%)
dizziness 11.1% (placebo 9.3%)
dysgeusia 4.4% (placebo 9.3%)
NCT00369577 · Phase 2 · registry result, not featured evidence
10 mg
dizziness 75% (placebo 35.7%)
dysgeusia 75% (placebo 0%)
somnolence 75% (placebo 21.4%)
NCT00444028 · Phase 1 · registry result, not featured evidence
5 mg
dizziness 57.1% (placebo 35.7%)
fatigue 42.9% (placebo 7.1%)
dysgeusia 28.6% (placebo 0%)
NCT00444028 · Phase 1 · registry result, not featured evidence
2.5 mg
dizziness 50% (placebo 35.7%)
nausea 50% (placebo 0%)
dysgeusia 33.3% (placebo 0%)
NCT00444028 · Phase 1 · registry result, not featured evidence
1.25 mg
dizziness 25% (placebo 35.7%)
dysgeusia 25% (placebo 0%)
headache 25% (placebo 14.3%)
NCT00444028 · Phase 1 · registry result, not featured evidence
0.625 mg
dizziness 28.6% (placebo 35.7%)
disturbance in attention 14.3% (placebo 7.1%)
dysgeusia 14.3% (placebo 0%)
NCT00444028 · Phase 1 · registry result, not featured evidence
40mge
headache 18.5% (placebo 15.7%)
akathisia 11.3% (placebo 51.2%)
nausea 11.3% (placebo 7.1%)
NCT00549718 · Phase 3 · monotherapy
show 41 more results
120mg
akathisia 24.2% (placebo 51.2%)
headache 16.9% (placebo 15.7%)
somnolence 14.5% (placebo 5.5%)
NCT00549718 · Phase 3 · monotherapy
80mg
akathisia 17.4% (placebo 51.2%)
headache 13.2% (placebo 15.7%)
sedation 10.7% (placebo 4.7%)
NCT00549718 · Phase 3 · monotherapy
40 mg
headache 21.8% (placebo 21.6%)
insomnia 12.6% (placebo 11.2%)
akathisia 11.8% (placebo 0.9%)
NCT00615433 · Phase 3 · monotherapy
120 mg
akathisia 22.9% (placebo 0.9%)
headache 17.8% (placebo 21.6%)
somnolence 15.3% (placebo 4.3%)
NCT00615433 · Phase 3 · monotherapy
insomnia 21.4%
sedation 21.4%
stiffness in jaw 14.3%
NCT02199743 · Phase 4 · registry result, not featured evidence
nausea 27.3%
headache 15.2%
insomnia 12.1%
NCT01569659 · Phase 4 · registry result, not featured evidence
40 mg
nausea 12.7% (placebo 2.7%)
anxiety 10% (placebo 8%)
akathisia 9.1% (placebo 1.8%)
NCT01911429 · Phase 3 · registry result, not featured evidence
80 mg
nausea 14.4% (placebo 2.7%)
somnolence 11.5% (placebo 5.4%)
headache 10.6% (placebo 12.5%)
NCT01911429 · Phase 3 · registry result, not featured evidence
extrapyramidal disorder 17%
consitpation 12.9%
insomnia 9.8%
NCT02002832 · Phase 3 · registry result, not featured evidence
40-mg or 80-mg
insomnia 11.3%
akathisia 11%
nasopharyngitis 10.6%
NCT01614912 · Phase 3 · registry result, not featured evidence
40 mg
headache 9.3% (placebo 7.9%)
constipation 8.7% (placebo 7.9%)
akathisia 7.3% (placebo 3.3%)
NCT01614899 · Phase 3 · registry result, not featured evidence
80 mg
akathisia 10.4% (placebo 3.3%)
nausea 7.8% (placebo 4.6%)
anxiety 7.1% (placebo 5.3%)
NCT01614899 · Phase 3 · registry result, not featured evidence
20 mg
insomnia 15.8% (placebo 21.4%)
headache 9.9% (placebo 7.1%)
anxiety 7.9% (placebo 6.3%)
NCT01821378 · Phase 3 · registry result, not featured evidence
80-160 mg
akathisia 10.6% (placebo 1.8%)
insomnia 10.6% (placebo 21.4%)
nausea 8.6% (placebo 3.6%)
NCT01821378 · Phase 3 · registry result, not featured evidence
headache 5.6%
diarrhoea 3.7%
influenza 3.7%
NCT01485640 · Phase 3 · registry result, not featured evidence
akathisia 5.2%
schizophrenia 4.2%
nasopharyngitis 2.6%
NCT01566162 · Phase 3 · registry result, not featured evidence
schizophrenia 6.9% (placebo 7.8%)
insomnia 6.3% (placebo 7.1%)
anxiety 4.2% (placebo 2.8%)
NCT01435928 · Phase 3 · registry result, not featured evidence
160 mg
headache 13.9%
akathisia 10.1%
insomnia 8.9%
NCT00789698 · Phase 3 · registry result, not featured evidence
80 mg
akathisia 15.3%
headache 6.9%
insomnia 6.9%
NCT00789698 · Phase 3 · registry result, not featured evidence
40/40
nausea 13.9%
headache 9.7%
somnolence 9.7%
NCT01143077 · Phase 3 · registry result, not featured evidence
40/80
insomnia 18.4%
akathisia 14.9%
headache 11.5%
NCT01143077 · Phase 3 · registry result, not featured evidence
80/80
nausea 18.5%
insomnia 14.8%
akathisia 13.6%
NCT01143077 · Phase 3 · registry result, not featured evidence
nausea 16.7%
insomnia 15.8%
sedation 14.6%
NCT00641745 · Phase 3 · registry result, not featured evidence
160 mg
headache 9.9% (placebo 10.7%)
akathisia 7.4% (placebo 0.8%)
vomiting 7.4% (placebo 5%)
NCT00790192 · Phase 3 · registry result, not featured evidence
80 mg
insomnia 11.2% (placebo 9.1%)
headache 9.6% (placebo 10.7%)
akathisia 8% (placebo 0.8%)
NCT00790192 · Phase 3 · registry result, not featured evidence
40 mg
insomnia 14.2% (placebo 14.4%)
schizophrenia 11.8% (placebo 18.9%)
nasopharyngitis 10.2% (placebo 9.8%)
NCT00711269 · Phase 3 · registry result, not featured evidence
80 mg
insomnia 19.1% (placebo 14.4%)
schizophrenia 19.1% (placebo 18.9%)
akathisia 11.5% (placebo 4.5%)
NCT00711269 · Phase 3 · registry result, not featured evidence
flexible dose
nausea 33.3%
NCT01731119 · Phase 2 · registry result, not featured evidence
80 mg
bronchitis 6.8%
nausea 6.8%
sedation 6.8%
NCT00088621 · Phase 2 · registry result, not featured evidence
80 mg
nausea 16.7% (placebo 3.3%)
constipation 11.1% (placebo 5.6%)
headache 11.1% (placebo 10%)
NCT00088634 · Phase 2 · registry result, not featured evidence
40 mg
dizziness 18.2%
headache 15.2%
nasopharyngitis 12.1%
NCT00044005 · Phase 2 · registry result, not featured evidence
80 mg
headache 15.2%
depression 12.1%
oropharyngeal pain 9.1%
NCT00044005 · Phase 2 · registry result, not featured evidence
20 mg
headache 15.6%
insomnia 9.4%
nasopharyngitis 9.4%
NCT00044005 · Phase 2 · registry result, not featured evidence
headache 21.1% (placebo 33.3%)
dyspepsia 11.3% (placebo 9.7%)
nausea 11.3% (placebo 11.1%)
NCT00044044 · Phase 2 · registry result, not featured evidence
headache 23.9% (placebo 33.3%)
sedation 16.4% (placebo 8.3%)
agitation 13.4% (placebo 4.2%)
NCT00044044 · Phase 2 · registry result, not featured evidence
headache 23.9% (placebo 33.3%)
sedation 21.1% (placebo 8.3%)
akathisia 18.3% (placebo 9.7%)
NCT00044044 · Phase 2 · registry result, not featured evidence
40 mg
somnolence 75% (placebo 33.3%)
blood prolactin increased 12.5% (placebo 22.2%)
irritability 12.5% (placebo 0%)
NCT02174510 · Phase 1 · registry result, not featured evidence
80 mg
somnolence 100% (placebo 33.3%)
blood prolactin increased 83.3% (placebo 22.2%)
dizziness 25% (placebo 0%)
NCT02174510 · Phase 1 · registry result, not featured evidence
20 mg
somnolence 62.5% (placebo 33.3%)
blood prolactin increased 12.5% (placebo 22.2%)
feeling hot 12.5% (placebo 0%)
NCT02174510 · Phase 1 · registry result, not featured evidence
40mg
somnolence 100% (placebo 0%)
blood prolactin increased 60% (placebo 25%)
restlessness 60% (placebo 0%)
NCT02174523 · Phase 1 · registry result, not featured evidence
somnelence 41.9%
sedation 18.1%
nausea 17.1%
NCT01620060 · Phase 1 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 6 weeks versus 0.0119 weeks.
  5. ePopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Loxapine (Adasuve)

PANSS-EC -8.6 vs -5.5 placebo score @ 0.0119wk10 mg
absolute change · score
NCT00628589 · Phase 3 · monotherapy
show 1 more result
-8.1 vs -5.5 placebo score @ 0.0119wk5 mg
NCT00628589 · Phase 3 · monotherapy
CGI-I 67% (n=112) vs 35.7% (n=115) placebo @ 0.0119wk10 mg
responder rate · % of participants
NCT00628589 · Phase 3 · monotherapy · converted to % from 75 Participants as posted
show 3 more results
62.5% (n=40) vs 20.9% (n=43) placebo @ 0.0119wk*10 mg
NCT00369577 · Phase 2 · registry result, not featured evidence · converted to % from 25 Participants as posted
56.9% (n=116) vs 35.7% (n=115) placebo @ 0.0119wk*5 mg
NCT00628589 · Phase 3 · monotherapy · converted to % from 66 Participants as posted
48.9% (n=45) vs 20.9% (n=43) placebo @ 0.0119wk*5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence · converted to % from 22 Participants as posted
PANSS-EC -8.56 vs -4.98 placebo PANSS units @ 0.0119wk10 mg
absolute change · PANSS units
NCT00369577 · Phase 2 · registry result, not featured evidence
show 1 more result
-6.71 vs -4.98 placebo PANSS units @ 0.0119wk5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
BARS -2.02 vs -0.93 placebo score @ 0.0119wk10 mg
absolute change · score
NCT00369577 · Phase 2 · registry result, not featured evidence
show 1 more result
-1.53 vs -0.93 placebo score @ 0.0119wk5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
CGI-I 2.28 vs 3.19 placebo CGI-I Units (7=worse, 1=better) @ 0.0119wk10 mg
absolute value · CGI-I Units (7=worse, 1=better)
NCT00369577 · Phase 2 · registry result, not featured evidence
show 1 more result
2.53 vs 3.19 placebo CGI-I Units (7=worse, 1=better) @ 0.0119wk5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence

Lurasidone

CGI-S -1.31 vs -0.73 placebo score @ 6wk160 mg
absolute change · score
NCT01821378 · Phase 3 · registry result, not featured evidence
show 20 more results
-1.7 vs -0.9 placebo score @ 6wk160 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
-1.1 vs -1 placebo score @ 6wk40mg
NCT00549718 · Phase 3 · monotherapy
-1.5 vs -1.1 placebo score @ 6wk40 mg
NCT00615433 · Phase 3 · monotherapy
-0.97 vs -0.5 placebo score @ 6wk40 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
-0.86 vs -0.79 placebo score @ 6wk40 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
-1.2 vs -1 placebo score @ 6wk120mg
NCT00549718 · Phase 3 · monotherapy
-1.4 vs -1.1 placebo score @ 6wk120 mg
NCT00615433 · Phase 3 · monotherapy
-1.4 vs -1 placebo score @ 6wk80mg
NCT00549718 · Phase 3 · monotherapy
-0.92 vs -0.5 placebo score @ 6wk80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
-0.97 vs -0.79 placebo score @ 6wk80 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
-0.83 vs -0.73 placebo score @ 6wk80 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
-1.5 vs -0.9 placebo score @ 6wk80 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
-0.6 vs -0.2 placebo score @ 6wk80 mg
NCT00088634 · Phase 2 · registry result, not featured evidence
-0.93 vs -0.73 placebo score @ 6wk20 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
-1.3 vs -0.73 placebo score @ 6wk80-160 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
0.44 vs 0.74 placebo score @ 28wk
NCT01435928 · Phase 3 · registry result, not featured evidence
-1.9 vs -1.6 Quetiapine score @ 52wk
NCT00789698 · Phase 3 · registry result, not featured evidence
-0.5 vs -0.7 placebo score @ 6wk
NCT00044044 · Phase 2 · registry result, not featured evidence
-0.4 vs -0.7 placebo score @ 6wk
NCT00044044 · Phase 2 · registry result, not featured evidence
-0.8 vs -0.7 placebo score @ 6wk
NCT00044044 · Phase 2 · registry result, not featured evidence
PANSS Total -21.7 vs -14.4 placebo score @ 6wk160 mg
absolute change · score
NCT01821378 · Phase 3 · registry result, not featured evidence
show 24 more results
-26.5 vs -10.3 placebo score @ 6wk160 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
-19.2 vs -17 placebo score @ 6wk40mg
NCT00549718 · Phase 3 · monotherapy
-25.7 vs -16 placebo score @ 6wk40 mg
NCT00615433 · Phase 3 · monotherapy
-18.6 vs -10.5 placebo score @ 6wk40 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
-17.9 vs -13.1 placebo score @ 6wk40 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
-6.1 vs -2.5 placebo score @ 6wk40 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
-20.5 vs -17 placebo score @ 6wk120mg
NCT00549718 · Phase 3 · monotherapy
-23.6 vs -16 placebo score @ 6wk120 mg
NCT00615433 · Phase 3 · monotherapy
-23.4 vs -17 placebo score @ 6wk80mg
NCT00549718 · Phase 3 · monotherapy
-18.3 vs -10.5 placebo score @ 6wk80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
-17.3 vs -13.1 placebo score @ 6wk80 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
-14.4 vs -14.4 placebo score @ 6wk80 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
-22.2 vs -10.3 placebo score @ 6wk80 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
-4.3 vs -2.5 placebo score @ 6wk80 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
-14.1 vs -5.5 placebo score @ 6wk80 mg
NCT00088634 · Phase 2 · registry result, not featured evidence
-17.6 vs -14.5 placebo score @ 6wk20 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
-31.2 vs -34.9 Risperidone score @ 6wk
NCT02002832 · Phase 3 · registry result, not featured evidence
-24.9 vs -14.5 placebo score @ 6wk80-160 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
8.3 vs 12.4 placebo score @ 28wk
NCT01435928 · Phase 3 · registry result, not featured evidence
-34.6 vs -25.7 Quetiapine score @ 52wk
NCT00789698 · Phase 3 · registry result, not featured evidence
-7.1 vs -12.3 placebo score @ 6wk
NCT00044044 · Phase 2 · registry result, not featured evidence
-7.2 vs -12.3 placebo score @ 6wk
NCT00044044 · Phase 2 · registry result, not featured evidence
-13.6 vs -12.3 placebo score @ 6wk
NCT00044044 · Phase 2 · registry result, not featured evidence
-26.42 vs -27.33 quetiapine XR, QXR score @ 6wk
NCT03465787 · Phase 3 · sponsor-reported, not registry data
BACS Composite -2.002433521 score @ 4wk
absolute change · score
No placebo or comparator arm
NCT02199743 · Phase 4 · registry result, not featured evidence
PANSS Positive Subscale 24.2 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT01569659 · Phase 4 · registry result, not featured evidence
PANSS Positive -6.3 vs -3.1 placebo score @ 6wk40 mg
absolute change · score
NCT01911429 · Phase 3 · registry result, not featured evidence
show 3 more results
-2 vs -0.6 placebo score @ 6wk40 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
-6.3 vs -3.1 placebo score @ 6wk80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
-1.4 vs -0.6 placebo score @ 6wk80 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
PANSS 20 63.9% (n=108) vs 61.6% (n=112) placebo @ 6wk40 mg
responder rate · % of participants
NCT01911429 · Phase 3 · registry result, not featured evidence · converted to % from 69 number of participants as posted
show 3 more results
44.3% (n=106) vs 61.6% (n=112) placebo @ 6wk*80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence · converted to % from 47 number of participants as posted
44% (n=101) vs 73% (n=112) placebo @ 6wk20 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
53% (n=198) vs 73% (n=112) placebo @ 6wk80-160 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
PQLES Total 5.6 vs 0.3 placebo score @ 6wk40 mg
absolute change · score
NCT01911429 · Phase 3 · registry result, not featured evidence
show 1 more result
6.1 vs 0.3 placebo score @ 6wk80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
CGAS 11.3 vs 7.5 placebo score @ 6wk40 mg
absolute change · score
NCT01911429 · Phase 3 · registry result, not featured evidence
show 1 more result
11.9 vs 7.5 placebo score @ 6wk80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
PANSS General Psychopathology -8.1 vs -5.3 placebo score @ 6wk40 mg
absolute change · score
NCT01911429 · Phase 3 · registry result, not featured evidence
show 5 more results
-8.8 vs -6.3 placebo score @ 6wk40 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
-2.4 vs -1 placebo score @ 6wk40 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
-8.1 vs -5.3 placebo score @ 6wk80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
-7.9 vs -6.3 placebo score @ 6wk80 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
-1.2 vs -1 placebo score @ 6wk80 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
PANSS Marder Uncontrolled Hostility/Excitement -0.6 vs -2.4 placebo score @ 6wk40 mg
absolute change · score
NCT01911429 · Phase 3 · registry result, not featured evidence
show 1 more result
-1.7 vs -2.4 placebo score @ 6wk80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
PANSS Total -28.4 score @ 32wk40-mg or 80-mg
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT01614912 · Phase 3 · registry result, not featured evidence
show 1 more result
-8.4 score @ 12wk
NCT01566162 · Phase 3 · registry result, not featured evidence
CGI-S -1.46 score @ 32wk40-mg or 80-mg
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT01614912 · Phase 3 · registry result, not featured evidence
show 1 more result
-0.48 score @ 12wk
NCT01566162 · Phase 3 · registry result, not featured evidence

+ 19 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Loxapine (Adasuve)'s landscape · Lurasidone's landscape